(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a session on non-beta emitter PSMA radioligand therapy. Dr.

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a session on non-beta emitter PSMA radioligand therapy. Dr. David ...

Additionally, multivariable analyses demonstrated that detectable ctDNA before radical cystectomy was associated with a higher risk of nodal disease (OR 5.4, 95% CI 1.9-18.2; p = 0.003) and locally ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

(UroToday.com) The Interdisciplinary Genitourinary Cancer Forum 2025, held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 2: Local Treatments. Dr. Peter Carroll ...

(UroToday.com) The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 6: ...

Pedro Barata speaks with Tian Zhang about the PDIGREE phase III adaptive trial. This cooperative group study enrolled over 1,000 patients across 46 states over five years, representing a collaborative ...

Zachary Klaassen interviews Nicholas James about applying the ArteraAI prostate test to high-risk M0 prostate cancer patients from STAMPEDE. Dr. James explains how they analyzed M0 patients receiving ...

Pathology Workup for Metastatic CRPC: Focus on Neuroendocrine Transformation - Himisha Beltran ...

Radiation vs Systemic Therapy for Isolated Pelvic Recurrence After Cystectomy - Andrea Necchi & Comron Hassanzadeh ...

At ASCO 2025, Novartis is presenting data from 60 abstracts across its oncology and hematology pipeline, showcasing key updates on Kisqali in younger breast cancer patients, earlier use of Pluvicto ...